Benefits of Citicoline in Ischemic Stroke Management
DOI:
https://doi.org/10.55175/cdk.v51i5.1056Keywords:
Citicoline, electrolite imbalance, ischemic strokeAbstract
Background: Stroke is the third most common disease after heart disease and cancer and the main cause of disability worldwide. The most common type of stroke, which accounts for around 85%-87% of cases, is ischemic stroke (IS). This report is to examine the benefits of citicoline for IS patients. Case: A 63-year-old male was admitted with a diagnosis of IS and electrolyte disturbances. General treatment is semi-Fowler’s position, oxygen, and maintaining fluid and nutritional intake. Specific management is RL infusion 20 gtt/minute, candesartan 1x16 mg, clopidogrel 1x75 mg, omeprazole 40 mg/24 h intravenous (IV), and citicoline 500 mg/12 h IV. The patient showed clinical improvement. Method: Articles in PubMed, Cochrane, and Google Scholar in February-April 2022 were searched to find relevant studies to be evaluated with inclusion and exclusion criteria. The full text was obtained and critically reviewed with the evidence-based medicine guidelines. The results are limited to systematic reviews and meta-analyses. Results: Five studies were deemed valid, important, and applicable. However, the quality of these studies varies. Conclusion: All studies show that citicoline use could potentially improve clinical outcomes in IS patients.
Downloads
References
l. Mukherjee D, Patil CG. Epidemiology and the global burden of stroke. World Neurosurg. 2011;76 (suppl):85–90.
Feigin VL, Lawes CM, Bennett DA, Anderson CS. Stroke epidemiology: A review of population-based studies of incidence, prevalence, and case-fatality in the late 20th century. Lancet Neurol. 2003;2: 43–53.
Davalos A, Alvarez-Sabin J, Castillo J, Díez-Tejedor E, Ferro J, Martínez-Vila E, et al, for the International Citicoline Trial on Acute Stroke (ICTUS) Trial Investigators. Citicoline in the treatment of acute ischaemic stroke: an international, randomized, multicentre, placebo-controlled study (ICTUS trial). Lancet 2012;380:349–57.
Lees KR, Bluhmki E, von Kummer R, Brott TG, Toni D, Grotta JC, et al, and the ECASS, ATLANTIS, NINDS and EPITHET rt-PA Study Group. Time to treatment with intravenous alteplase and outcome in stroke: An updated pooled analysis of ECASS, ATLANTIS, NINDS, and EPITHET trials. Lancet 2010;375:1695–703.
Agarwal A, Vishnu VY, Sharma J, Bhatia R, Garg A, Dwivedi S, et al. Citicoline in acute ischemic stroke: A randomized controlled trial. PLoS ONE 2022;17(5):e0269224.
Secades JJ, Alvarez-Sabín J, Castillo J, Díez-Tejedor E, Martínez-Vila E, Ríos J, et al. Citicoline for acute ischemic stroke: A systematic review and formal meta-analysis of randomized, double-Blind, and placebo-controlled trials. J Stroke Cerebrovasc Dis. 2016;25(8):1984-96. DOI: 10.1016/j.jstrokecerebrovasdis.2016.04.010.
Sahota P, Savitz SI. Investigational therapies for ischemic stroke: Neuroprotection and neurorecovery. Neurotherapeutics 2011;8:434–51.
Saver JL. Target brain: Neuroprotection and neurorestoration in ischemic stroke. Rev Neurol Dis. 2010;7(suppl 1):14–21.
Da´valos A, Castillo J, Alvarez-Sabı´n J, Secades JJ, Mercadal J, Lopez S, et al. Oral citicoline in acute ischemic stroke: An individual patient data pooling analysis of clinical trials. Stroke 2002;33:2850–7.
Gutie´rrez-Ferna´ndez M, Rodrı´guez-Frutos B, Fuentes B, Vallejo-Cremades MT, Alvarez-Grech J, Expósito-Alcaide M, et al. CDP-choline treatment induces brain plasticity markers expression in experimental animal stroke. Neurochem Int. 2012;60:310–7.
Clark WM, Warach SJ, Pettigrew LC, Gammans RE, Sabounjian LA. A randomized dose-response trial of citicoline in acute ischemic stroke patients. Neurology 1997;49:671–78.
Clark WM, Williams BJ, Selzer KA, Zweifler RM, Sabounjian LA, Gammans RE. A randomized efficacy trial of citicoline in patients with acute ischemic stroke. Stroke 1999;30:2592–7.
Clark WM, Wechsler LR, Sabounjian LA, Schwiderski UE. A phase III randomized efficacy trial of 2000 mg citicoline in acute ischemic stroke patients. Neurology 2001;57:1595–602.
Herskovits AZ, Guarente LP. SIRT1 in neurodevelopment and brain senescence. Neuron 2014;81:471–83. DOI: 10.1016/j.neuron.2014.01.028.
Xu J, Jackson CW, Khoury N, Escobar I, Perez-Pinzon MA. Brain SIRT1 mediates metabolic homeostasis and neuroprotection. Front Endocrinol. 2018;9:702. DOI: 10.3389/fendo.2018.00702.
Bonda DJ, Lee HG, Camins A, Pallàs M, Casadesus G, Smith MA, et al. The sirtuin pathway in ageing and Alzheimer disease: Mechanistic and therapeutic considerations. Lancet Neurol. 2011;10:275–9. DOI: 10.1016/S1474-4422(11)70013-8.
Donmez G, Arun A, Chung CY, McLean PJ, Lindquist S, Guarente L. SIRT1 protects against α-synuclein aggregation by activating molecular chaperones. J Neurosci. 2012;32: 124–32. DOI: 10.1523/JNEUROSCI.3442-11.2012.
Hurtado O, Hernández-Jiménez M, Zarruk JG, Cuartero MI, Ballesteros I, Camarero G, et al. Citicoline (CDP-choline) increases sirtuin1 expression concomitant to neuroprotection in experimental stroke. J Neurochem. 2013;126:819–26. DOI: 10.1111/jnc.12269.
Secades JJ. Citicoline: Pharmacological and clinical review, 2016 update. Rev Neurol. 2016;63:1–73.
Synoradzki K, Grieb P. Citicoline: A superior form of choline? Nutrients 2019;11:1569. DOI: 10.3390/nu11071569.
Blusztajn JK, Slack BE, Mellott TJ. Neuroprotective actions of dietary choline. Nutrients 2017;9:815. DOI: 10.3390/nu9080815.
Roohi-Azizi M, Torkaman-Boutorabi A, Akhondzadeh S, Nejatisafa AA, Sadat-Shirazi MS, Zarrindast MR. Influence of citicoline on citalopram-induced antidepressant activity in depressive-like symptoms in male mice. Physiol Behav. 2018;195:151–7. DOI: 10.1016/j.physbeh.2018.08.002.
Hurtado O, Moro MA, Cárdenas A, Sanchez V, Fernández-Tomé P, Leza JC, et al. Neuroprotection afforded by prior citicoline administration in experimental brain ischemia: Effects on glutamate transport. Neurobiol Dis. 2005;18:336–45.
Jasielski P, Piędel F, Piwek M, Rocka A, Petit V, Rejdak K. Application of citicoline in neurological disorders: A systematic review. Nutrients 2020;12(10):3113. DOI: 10.3390/nu12103113.
Sharma A. How to write an article: An introduction to basic scientific medical writing. J Minim Access Surg. 2019;15(3):242-8. DOI: 10.4103/jmas.JMAS_91_18. =
Theola J, Hermanadi MI, Gibran K, Ihsan S. Clinical outcomes of ivermectin in Covid-19 treatment: An evidence-based case report from systemic reviews and meta-analyses. J Ilmiah Mahasiswa Kedokt Indon. 2021;9:2. DOI: 10.53366/jimki.v9i2.411.
Padhy BM, Mohanty RR, Das S, Meher BR. Therapeutic potential of ivermectin as add on treatment in COVID 19: A systematic review and meta-analysis. J Pharm Pharm Sci. 2020;23:462-9. DOI: 10.18433/jpps31457.
Martí-Carvajal AJ, Valli C, Martí-Amarista CE, Solà I, Martí-Fàbregas J, Bonfill Cosp X. Citicoline for treating people with acute ischemic stroke. Cochrane Database Syst Rev. 2020;8(8):CD013066. DOI: 10.1002/14651858.CD013066.pub2.
Sagaro GG, Amenta F. Choline-containing phospholipids in stroke treatment: A systematic review and meta-analysis. J Clin Med. 2023;12:2875.
Premi E, Cantoni V, Benussi A, Gilberti N, Vergani V, Delrio I, et al. Citicoline treatment in acute ischemic stroke: A randomized, single-blind TMS study. Front Neurol. 2022;13:915362. DOI: 10.3389/fneur.2022.915362.
Secades JJ, Alvarez-Sabín J, Rubio F, Lozano R, Dávalos A, Castillo J. Citicoline in intracerebral haemorrhage: A double blind, randomized, placebo controlled, multi-centre pilot study. Cerebrovasc Dis. 2006;21(5-6):380-5. DOI: 10.1159/000091547.
Alvarez-Sabín J, Román GC. The role of citicoline in neuroprotection and neurorepair in ischemic stroke. Brain Sci. 2013;3(3):1395-414. DOI: 10.3390/brainsci3031395.
Secades JJ, Gareri P. Citicoline: Pharmacological and clinical review, 2022 update. Rev Neurol. 2022;75 (Suppl. 5):0-89. DOI: 10.33588/rn.75S05.2022311.
Kanyal N. The science of ischemic stroke: Pathophysiology & pharmacological treatment. Int J Pharm Res Rev. 2015;4(10):65-84.
Downloads
Published
How to Cite
Issue
Section
License
Copyright (c) 2024 endyjulianto, jekson Martiar Siahaan, 3Putri Chairani Eyanoer
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
